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Abstract: Complexes containing the anions of 5-benzoylamido-l,3,4-thiadiazole-2-sulfonamide and 5-(3-
nitro-benzoylamido)-l,3,4-thiadiazole-2-sulfonamid as ligands, and V(IV); Cr(III); F(III); COO0; Ni(II);
Cu(II) and Ag(I) were synthesized and characterized by standard procedures (elemental analysis; IR,
electronic, and EPR spectroscopy; TG, magnetic and conductimetric measurements). The original
sulfonamides and their metal complexes are strong inhibitors oftwo carbonic anhydrase (CA) isozymes, CA
and II.
Introduction
1,3,4-Thiadiazol-2-sulfonamid derivatives such as acctazolamid 1, benzolamid 2 or
chlorzolamid 3 arc clinically used pharmacological agents, which owe their biological activity to the
inhibition of the zinc enzyme carbonic anhydras (CA, EC 4.2.1.1).
-4 Since many isoforms of CA are
presently known in higher vertebrates, and since the physiological function for some of them is rather
unclear, novel types of sulfonamid-6’ as well as non-sulfonamid CA inhibitors arc designed in order to
select a series of compounds specific for the different CA isocnzymes, the final goal being the
comprehension of the physiological functions of each of them and possibly their control. Among these,
metal complexes of heterocyclic sulfonamidcs of type 1-3 exhibited valuable inhibitory properties against
several CA isozymes.
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Since there is a net discrimination of sulfonamide inhibitors as well as their metal complexes
towards the rapid type CA isozymes (such as CA II and CA IV) versus the low type ones (such as CA I and
235 III), our approach might lead to more specific inhibitors.
In this paper we report the preparation of metal complexes oftwo new sulfonamide CA inhibitors,
i.e., 5obenzoylamino-l,3,4-thiadiazole-2-sulfonamide 4, and its 3onitrophenyl- analogue 5, which were
recently reported by this group, and which possess good CA inhibitory properties. The V(IV), Cr(III),
Fe(III), Co(II), Ni(II), Cu(II) and Ag(I) complexes containing the conjugate bases ofthe two sulfonamides 4
and 5 were obtained and characterized by standard procedures (elemental analysis, IR, electronic, and EPR
spectroscopy; TG, magnetic and conductimetric measurements). The new complexes possess good inhibitory
properties against the red cell isozymes CA and CA II, which are the predominant CAs is mammalian
blood and secretory organs.
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Materials and Methods
IR spectra of KBr pellets were recorded with a Specord MS0 or Perkin-Elmer 16PC FTIR
instruments, in the range 200-4000 cm". Solution electronic spectra were recorded with a Specord M400 or
Cary 3 spectrophotometers interfaced with a PC. Electronic spectra were obtained by the diffuse reflectance
technique in MgO as a reference, with a Perkin Elmer Lambda 15 apparatus, in the range 200-900 cm.
Conductimetric measurements were done in mM DMF solutions of the complex at 25C with a Fisher
conductimeter. EPR spectra of a crystalline powder were recorded on a Varian E-9 spectrometer at room
temperature. The field was calibrated using crystalline diphenylpicrylhydrazyl (g 2.0036). Magnetic
susceptibility measurements were carried out at room temperature with a fully automated AZTEC DSM8
pendulum-type susceptometer. Mercury(II) tetrakis(thiocyanato)cobaltate(II) was used as a susceptibility
standard. Corrections for the diamagnetism were estimated from Pascal’s constants.
2 Elemental analyses
were done by combustion for C,H,N with an automated Carlo Erba analyzer, and gravimetrically for the
metal ions, and were _+ 0.4% of the theoretical values. Thermogravimetric measurements were done in air, at
a heating rate of 10C/min., with a Perkin Elmer 3600 thermobalance.
Acetazolamide used in the enmatic assay as standard was from Sigma. Sulfonamides 4 and 5
were prepared as described previously. Metal salts and solvents were from Merck. Human CA I and CA II
cDNAs were expressed in Escherichia coil strain BL21 (DE3) from the plasmids pACA/HCA I and
pACA/HCA II (the two plasmids were a gift from Prof. Sven Lindskog, Umea University, Sweden). Cell
growth conditions were those described by Lindskog’s group,
3 and enzymes were purified by affinity
chromatography according to the method of Khalifah et al.
4 Enzyme concentrations were determined
spectrophotometrically at 280 nm, using a molar absorptivity of 49 mM. cm" for CA I and 54 mM.cm"
for CA II, respectively, based on Mr 28.85 kDa for CA I, and 29.3 kDa for CA II, respectively.
s
Initial rates of 4-nitrophenyl acetate hydrolysis were monitored spectrophotometrically, at 400 nm
and 25C, with a Ca 3 apparatus interfaced with an IBM compatible PC by the method of Pocker and
Stone. 6. 10
-2 and 10 M solution of the substrate were prepared in anhydrous acetonitrile. A molar
absorption coefficient e 18,400 M’.cm" was used for the 4-nitrophenolate formed by hydrolysis, in the
conditions of the experiments (pH 7.80), as reported by Pocker and Stone.
6 Non-enzymatic hydrolysis rates
were always subtracted from the observed rates. Duplicate experiments were done for each inhibitor, and the
values reported throughout the paper are the averages of such results. ICs0 represents the molarity of inhibitor
producing a 50% decrease ofenzyme catalyzed hydrolysis of4-nitrophenyl acetate.
General procedure for the preparation of metal complexes 6-23
10 mMoles of sulfonamide 4 or 5 were suspended in 25 mL MeOH and the calculated amount of N NaOH
solution was added in order to obtain the monosodium salt RSO2NHNa. This was treated thereafter with an
aqueous solution of the metal salt (AgNO3; chlorides for Cu(II), Co(II), and Ni(II), vanadyl and Cr(III)
sulfate; Fe(III) perchlorate), working at molar ratios M
n+ RSO2NH of l:l for the As(I) derivatives, 1:2 for
the divalent metal ions and V(IV), 1:3 for the trivalent metal ions, and 1:4 for Co(II) and Cu(II). The
reaction mixture was heated on a steam bath for 3 hours, then the precipitated complexes were filtered,
thoroughly washed with cold water and alcohol. Crystallization was not done as the only solvents in which
the complexes have good solubility are DMSO and DMF. The colored powders of complexes 6-23 melt
with decomposition at temperatures higher than 325 C.
Results and Discussion
The metal complexes containing the conjugate bases of sulfonamides 4 and 5 and transition metal
ions are shown in Table I, together with their elemental analysis data.
The newly prepared compounds, 6-23, were also characterized by IR-, electronic and EPR
spectroscopy, thermogravimetric (TG) and conductimetry. Some ofthese data are presented in Table II.
In the IR spectra of complexes 6-23, the major modifications, as compared to the spectra of the
sulfonamides 4 and 5 from which they were prepared, concern the two vibrations of the sulfonamido
moieties, shifted by 5-10 cm" (for the Sgy.metric vibration) and 5-15 cm" (for the asymmetric one),
respectively, towards lower wavenumbers, indicating that the deprotonated sulfonamido moieties of the
ligands interacts with the metal ions, as well as the shift of the C=N vibration in the spectra of the
complexes with 5-45 cm
"l towards lower wavenumbers (except for compounds 13 and 22) (Table II). The
amide vibrations (the most intense such bands are at 1670-1680 cm") of the complexes 6-19 appear
unchanged as compared to those of the sulfonamides 4 and 5 (data not shown), suggesting that these
moieties do not participate in coordination of the metal ions. Minor changes in the region 3100-3160m"
were also observed in the spectra of complexes 6-23, as the bands present in the spectra of sulfonamides 4
and 5 are present in those of complexes, but they are not well resolved, and have a smaller intensity (data,4. Jitanu, M. Ilies, F. Briganti et al. Metal-Based Drugs
not shown). This is due to deprotonation of the SO2NH: moiety and participation in the binding of
cations.,9.
/
Table I: Prepared complexes 6-23, containing the conjugate bases of sulfonamides 4 and 5, and their
elemental analysis data; bta stands for the sulfonamide deprotonated species of 4, and nbta for the
corresponding species of 5.
No. Complex Color Yield Analysis (calculated/found)
(%) %M’ %C
b %H
b %N
a’
6 [VO(bta)2 gray 78 8.0/8.1 34.1/34.1 2.2/2.3 17.7/17.3
7 [Cr(bta)3] green 82 5.7/5.4 35.9/35.5 2.3/2.1 18.6/18.4
$ [Fe(bta)3] brown 90 6.1/6.0 35.8/35.5 2.3/2.3 15.5/18.3
9 [Co(bta)2(OH2)2] pink 88 8.9/8.7 32.6/32.5 2.7/2.5 16.9/16.5
10 Na[Co(bta)] pink 71 6.2/6.1 34.$/35.1 2.2/2.0 18.0/17.6
11 [Ni(bta)(OH:)2] green 84 8.8/8.7 32.6/32.2 2.7/2.3 16.9/16.6
12 [Cu(bta)2] blue 82 10.0/9.7 34.3/34.2 2.2/1.9 17.7/17.6
13 Na2[Cu(bta)4] blue 69 5.1/4.7 34.8/34.5 2.2/2.0 18.0/17.7
14 [Ag(bta)] white 95 27.6/27.1 27.6/27.7 1.8/1.9 14.3/13.9
15 [VO(nbta),] gray 82 7.0/7.1 29.8/29.5 1.6/1.5 19.3/19.0
16 [Cr(nbta)] green 67 5.0/4.7 31.2/31.6 1.7/1.4 20.2/19.9
17 [Fe(nbta)a] brown 91 5.3/5.1 31.1/29.9 1.7/1.7 20.1/19.8
18 [Co(nbta)2(OH2)2] pink 82 7.8/7.5 28.7/2843 2.1/2.2 18.6/18.5
19 Na[Co(nbta)] pink 85 5.5/5.4 30.3/30.1 2.2/2.0 19.6/19.3
20 [Ni(nbta)2(OH:)2] green 94 7.8/7.4 28.7/28.4 2.1/2.3 18.6/18.3
21 [Cu(nbta)2] blue 89 8.3/8.4 28.2/27.8 1.5/1.4 18.3/18.0
22 Na2[Cu(nbta)] blue 75 4.4/4.2 30.4/30.0 1.6/1.6 19.7/19.4
23 [Ag(nbta)] white 95 24.7/24.5 24.7/24.8 1.3/1.0 16.0/15.8
aBy gravimetry (calculated/found); bBy combustion.
Solution electronic spectra ofthe complexes (Table II) prove the presence ofthe sulfonamido anions
RSO2NH" in the molecules of the new complexes 6-23, as bathochromic and hyperchromic effects of the
characteristic thiadiazole bands from 312-318 and 271-277 nm, respectively, are observed. The two bands
from the spectra of sulfonamides 4 and 5 undergo the same type of modifications when the spectra are
registered in the presence ofNaOH, when obviously the above mentioned anions are formed. This type of
behavior was previously evidenced for other sulfonamide complexes which were prepared via the
corresponding sodium salt.
9"1
Thermogravimetric (TG) analysis (Table II) demonstrated the presence of two coordinated water
molecules in the Co(II) complexes 9 and 15, as well as the Ni(II) ones 11 and 20. These water molecules are
lost in a single step between 180-190 C. The other prepared complexes did not show any weight loss under
240 C. At higher temperatures they decomposed by a complete oxidation to NiO, as well as oxidation of
the organic moieties present in their molecule (data not shown).
A detailed TG study was done for the Ni(II) complex 11, which showed three steps ofweight loss, described
below:
180C
[Ni(bta)2(OH2)2] --
[Ni(bta)2] + 2 H20 (1)
245C
[Ni0ata)2] -->
unidentified Ni(II) complex
2 C6HsCHO + unidentified Ni(II) complex (2)
250-700C
-o (3) NiO + CO2+ SO2 + N + H_O
The first step is the one in which the two water molecules are lost (an exothermic process), as
mentioned above. The anhydrous complex undergoes then a lost of benzaldehyde (step 2)at 245 C
(endothermic process; weight loss, found: 34.1%; ealc. for two benzaldehyd molecules: 33.9 %), with
formation of a highly unstable (unidentified) complex, which is further decomposed. Finally, the last step
involves the complete oxidation of this last complex to NiO and gaseous compounds (step 3).Vol. 4, No. 1, 1997 Metal Complexes ofS-Benzoylamino- and 5-(3-Nitrobenzoylamino-
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Table II: Spectroscopic, thermogravimetri and onductimetri data for compounds 4-23.
Comp. IR Spectra ,m" Electronic Spectra
b TG analysis Coaduetimetrv
d
(SO2)s" (SO2)as (C=N) E (nm) (lge) al./found M x m2x mol"1)
4 1180; 1370 1610 318 (3.56); 271 (3.48) e 6
6 1170; 1360 1600 341 (3.62); 303 (4.03) e 9
7 1170; 1360 1600 339 (3.89); 301 (4.11) e 10
$ 1160; 1350 1600 343 (3.80); 300 (4.08) e 7
9 1170; 1360 1600 341 (3.62); 276 (3.55) 5.4/5.5 7
10 1180; 1360 1600 340 (3.69); 281 (3.52) e 183
11 1170; 1360 1565 340 (3.75); 286 (3.70) 5.4/5.1 9
12 1180; 1350 1600 332 (3.61); 290 (3.66) e 11
13 1175; 1360 1610 340 (3.59); 308 (3.71) e 279
14 1170; 1360 1605 337 (3.58); 277 (3.52) e 11
5 1175; 1380 1620 312 (3.39); 256 (3.97) e 8
15 1170; 1360 1615 330 (3.48); 277 (4.01) e 14
16 1170; 1360 1610 340 (3.76); 284 (4.21) e 9
17 1160; 1360 1610 338 (3.72); 289 (4.09) e 12
18 1160; 1360 1615 345 (3.68); 284 (3.91) 4.7/4.5 10
19 1170; 1355 1600 338 (3.98); 270 (4.10) 175
211 1170; 1360 1585 332 (3.58); 285 (3.87) 4.8/4.6 13
21 1170; 1355 1610 346 (3.62); 290 (3.96) e
22 1170; 1350 1620 350 (3.43); 308 (4.10) e 250
23 1165; 1350 1600 338 (3.41); 269 (3.95) e 15
In KBr; bin DMSO; CWeight loss between 130-200 C;
d 10-3 M solution, in DMF, at 25C; No weight
loss seen under 250 C; Corresponding to two coordinated water molecules, lost at 180-190 C.
Table III: Diffuse reflectance spectra, magnetic moments and proposed geometries for complexes 4-10.
Complex Electronic spectra (, cm’l)a
eft (BM)
b Geometry
6 25,900; 15,500; 11,$00(sh) 1.85 square pyramidal
7 29,200; 23,700; 16,440 3.42 octahedral
8 24,650; 20,300; 10,600 5.77 octahedral
9 25,600; 20,500(sh); 15,600 4.89 octahedral
10 25,900; 20,800(sh); 15,900 4.90 octahedral
11 15,600; 11,400 3.48 octahedral
12 13,700 2.17 square planar
13 14,900 1.98 distorted tetrahedral
14 c d linear
15 25,800; 15,500; l,700(sh) 1.85 square pyramidal
16 29,400; 22,300; 17,200 3.40 octahedral
17 24,700; 20,800; 10,400 5.72 octahedral
18 25,900; 20,100(sh); 16,100 4.73 octahedral
19 26,500; 20,800(sh); 15,400 4.92 octahedral
20 16,100; 11,200 (sh) 3.44 octahedral
21 14,200 2.20 square planar
22 13,800 1.73 distorted tetrahedral
23 c d linear
aln MgO as standard material; bAt room temperature;
c No transitions seen; d Diamagnetic.,4. Jitanu, M. Ilies, F. Briganti et al. Metal-Based Drugs
Conductimetric data (Table II) showed the complexes 10 and 18 to behave as 1:1 electrolytes, the
complexes 13 and 22 as 2:1 electrolytes, and all the other new complexes, as well as the sulfonamides from
which they were prepared, as non-electrolytes.
The conjugate bases of the two sulfonamides 4 and 5, used as ligands for the preparation of the
complexes, probably act mono- or bidentately, as previously shown for the complexes containing main
group metal ions. When acting as monodentate ligands, the donor system is constituted by the sulfonamido
nitrogen atom, whereas when bidentate, by the endocyclic N-3 and the sulfonamidic nitrogen. It is quite
probable that the two ligands have the same behavior in their complexes with transition metal ions, reported
here. Monodentate behavior is present only for the two Cu(II) complexes 13 and 22, whereas in all other
compounds the ligands act bidentately. This behavior is supported by the spectroscopic, analytic and TG
data presented above.
In Table III diffuse reflectance electronic spectra, magnetic susceptibility data at room temperature
and the proposed geometries for the metal ions in the new complexes are presented.
Thus, the two vanady_l derivatives, 6 and 15, show an electronic spectrum characteristic of V(IV) in
square pyramidal geometry, which is confirmed by the magnetic susceptibility data.
9 The Cr(III) and
Fe(III) derivatives 7, 8, 16 and 17, as well as the Ni(II) and Co(II) complexes are in octahedral geometr..2as seen from both the electronic as well as magnetic data, typical for these ions in octahedral surrounding.
The two copper complexes in which the ligand acts monodentately, 13 and 22, are probably in a distorted
tetrahedral geometry, as they show only a broad band in the electronic spectrum, have magnetic moments
under 2.00 BM, and a large signal in the EPR spectrum with g_L 1.93 and gll 2"24"2’:
H20
/
.... ......
ON2
11,15,20
"’-’HNSO 2
HN ’.... ... NH
,,,- )
?,$, 10,16,17,1
R-SO2NH 2-
, NSO <
Cu" Cu......’NHSO2
,,,SO2NH
/ NH. R’SO2NH/ ’ R-SO2NH
12,21
The other two copper derivatives, 12 and 21, probably contain Cu(II) in square planar geometry,
4.s
as seen from the electronic spectroscopic and matnetic data of Table III. The AgO) derivatives 14 and 23
probably contain these ions in the linear geometry.’
Inhibition of isozymes CA and II with the newly synthesized inhibitors as well as standard
inhibitors acetazolamide I and benzolamide 2, are shown in Table IV.
From the inhibition data of Table IV, it is obvious that the new complexes act as strong inhibitors of both
isoymes, comparably with the standard (and very potent) CA inhibitor benzolamide, and much stronger ones
than the other clinically used compound, acetazolamide. No major differences were observed between the
two sulfonamides 4 and 5, except for the fact that the nitro-substituted compound 5 is slightly more active
than 4 (a trend generally also manifested by the complexes containing the conjugate bases of these
sulfonamides). This may be accounted on the acidification of the sulfonamido protons by the nitro
moiety.TM The less efficient inhibitors were the V(IV), Cr(III) (it should be noted that compounds 7 and 16
are the first chromium complexes of sulfonamides ever reported) and Ni(II) derivatives, whereas cations such
as Fe(III), Co(II), Cu(II) and Ag(I) led to the most active inhibitors.Vol. 4, No. 1, 1997 Metal Complexes ofS-Benzoylamino- and 5-(3-Nitrobenzoylamino-
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Table IV: Biological activity data of sulfonamide CA inhibitors and their metal complexes (ICso -the mean
of two different assays -represents the molarity of inhibitor producing a 50% decrease of enzyme specific
activity for the p-nitrophenyl acetate hydrolysis reaction).
Compound ICs0 (lxM)
CA I’ CA II’
1 (acetazolamide) 90 1.10
2 (benzolamide) 12 O. 10
4 9.0 0.15
$ 8.0 0.09
6 10.5 0.10
7 12.4 0.15
$ 3.5 0.09
9 1.5 0.06
10 2.9 0.05
11 8.0 0.13
12 4.3 0.05
13 3.2 0.04
14 1.8 0.03
15 10.0 0.08
16 12.5 0.09
17 2.5 0.03
18 1.8 0.04
19 1.4 0.04
20 7.6 0.11
21 1.5 0.02
22 1.8 0.01
23 2.4 0.03
’Human (cloned) isozyme;
Great differences between the two isozymes were also revealed, with CA II being much more
susceptible to inhibition by sulfonamides and metal complexes, as compared to CA I. Although CA I is a
relatively sulfonamide resistant enzyme,
2’3 it should be noted that several complexes reported here, such as
9, 14, 19, and 21, showed very good inhibition properties, although they also inhibited CA II quite
potently, so that isozyme-specificity was not achieved yet with this class of inhibitors.
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